Susceptibility testing of Aspergillus flavus: Inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 5, 2001, Pages 1456-1462

  Mosquera, J ^a   Warn, P A ^a   Morrissey, J ^a   Moore, C B ^a   Gil Lamaignere, C ^a   Denning, D W ^a  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; FUNGUS GROWTH; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FLAVUS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MICROBIAL; ITRACONAZOLE; MALE; MICE; MICROBIAL SENSITIVITY TESTS; STATISTICS;

EID: 0035029159     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.5.1456-1462.2001     Document Type: Article

References (29)

1. Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice
2. Invasive aspergillosis in immunocompromised patients
3. Invasive aspergillosis
4. Azole resistance in Candida
5. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis
6. Itraconazole resistance in Aspergillus fumigatus
7. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
8. Experimental murine invasive pulmonary aspergillosis
9. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
10. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method
11. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection
12. Invasive aspergillosis in patients with AIDS
13. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergitlosis
14. Aspergillus fumigatus and aspergillosis
15. In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304
16. The trailing end point phenotype in antifungal susceptibility testing is pH dependent
17. In-vitro activity of liposomal nystatin against Aspergillus species, abstr. P90
18. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole
19. Efficacy of SCH56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptibie and an itraconazole-resistant isolate of Aspergillus fumigatus
20. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models
21. Ketoconazole: A new imidazole antifungal agent has both prophylactic potential and therapeutic efficacy in keratomycosis of rabbits
22. Interpretation of trailing end points in antifungal susceptibility testing by the national committee for clinical laboratory standards method
23. Inactivity of terbinafine in a rat model of pulmonary aspergillosis
24. Many faces of pulmonary aspergillosis
25. Experimental avian aspergillosis
26. Antifungal drug resistance in pathogenic fungi
27. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis